Article
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Antimicrobial agents and chemotherapy - 1 Oct 2018
Krishnan Preethi, Pilot-Matias Tami, Schnell Gretja, Tripathi Rakesh, Ng Teresa I, Reisch Thomas, Beyer Jill, Dekhtyar Tatyana, Irvin Michelle, Xie Wangang, Larsen Lois, Mensa Federico J, Collins Christine
Abstract excerpt
Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to interferon, ribavirin, and/or sofosbuvir were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight registrational phase 2 and 3 clinical studies. High rates of sustained virologic response at 12 weeks postdosing (SVR12) were achieved with a <1%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.